Utility of Amino-Terminal Pro-Brain Natriuretic Peptide, Galectin-3, and Apelin for the Evaluation of Patients With Acute Heart Failure

Bleumink, 2004, Quantifying the heart failure epidemic: prevalence, incidence rate, lifetime risk and prognosis of heart failure The Rotterdam Study, Eur Heart J, 25, 1614, 10.1016/j.ehj.2004.06.038

Lloyd-Jones, 2002, Lifetime risk for developing congestive heart failure: the Framingham Heart Study, Circulation, 106, 3068, 10.1161/01.CIR.0000039105.49749.6F

Jessup, 2003, Heart failure, N Engl J Med, 348, 2007, 10.1056/NEJMra021498

MacIntyre, 2000, Evidence of improving prognosis in heart failure: trends in case fatality in 66 547 patients hospitalized between 1986 and 1995, Circulation, 102, 1126, 10.1161/01.CIR.102.10.1126

Khand, 2000, Is the prognosis of heart failure improving?, J Am Coll Cardiol, 36, 2284, 10.1016/S0735-1097(00)00995-5

Lee, 2005, Novel markers for heart failure diagnosis and prognosis, Curr Opin Cardiol, 20, 201, 10.1097/01.hco.0000161832.04952.6a

Maisel, 2002, Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure, N Engl J Med, 347, 161, 10.1056/NEJMoa020233

Januzzi, 2005, The N-Terminal Pro-BNP Investigation of Dyspnea in the Emergency Department (PRIDE) study, Am J Cardiol, 95, 948, 10.1016/j.amjcard.2004.12.032

Bettencourt, 2004, N-terminal-pro-brain natriuretic peptide predicts outcome after hospital discharge in heart failure patients, Circulation, 110, 2168, 10.1161/01.CIR.0000144310.04433.BE

Doust, 2005, How well does B-type natriuretic peptide predict death and cardiac events in patients with heart failure: systematic review, BMJ, 330, 625, 10.1136/bmj.330.7492.625

Bruneau, 1997, BNP gene expression is specifically modulated by stretch and ET-1 in a new model of isolated rat atria, Am J Physiol, 273, H2678

Mann, 1994, Basic mechanisms in congestive heart failure, Chest, 105, 897, 10.1378/chest.105.3.897

Sharma, 2004, Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction, Circulation, 110, 3121, 10.1161/01.CIR.0000147181.65298.4D

Chen, 2003, Novel role for the potent endogenous inotrope apelin in human cardiac dysfunction, Circulation, 108, 1432, 10.1161/01.CIR.0000091235.94914.75

Jessup, 2003, Aldosterone blockade and heart failure, N Engl J Med, 348, 1380, 10.1056/NEJMe030030

Foody, 2002, Beta-blocker therapy in heart failure: scientific review, JAMA, 287, 883, 10.1001/jama.287.7.883

McAlister, 2001, A systematic review of randomized trials of disease management programs in heart failure, Am J Med, 110, 378, 10.1016/S0002-9343(00)00743-9

Moss, 2002, Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction, N Engl J Med, 346, 877, 10.1056/NEJMoa013474

Weber, 2001, Cardioreparation in hypertensive heart disease, Hypertension, 38, 588, 10.1161/01.HYP.38.3.588

Testa, 1996, Circulating levels of cytokines and their endogenous modulators in patients with mild to severe congestive heart failure due to coronary artery disease or hypertension, J Am Coll Cardiol, 28, 964, 10.1016/S0735-1097(96)00268-9

Devaux, 1997, Upregulation of cell adhesion molecules and the presence of low grade inflammation in human chronic heart failure, Eur Heart J, 18, 470, 10.1093/oxfordjournals.eurheartj.a015268

Torre-Amione, 1996, Tumor necrosis factor-alpha and tumor necrosis factor receptors in the failing human heart, Circulation, 93, 704, 10.1161/01.CIR.93.4.704

Liu, 2005, Galectins as modulators of tumour progression, Nat Rev Cancer, 5, 29, 10.1038/nrc1527

Cooper, 2002, Galectinomics: finding themes in complexity, Biochim Biophys Acta, 1572, 209, 10.1016/S0304-4165(02)00310-0

Leffler, 2004, Introduction to galectins, Glycoconj J, 19, 433, 10.1023/B:GLYC.0000014072.34840.04

Hughes, 1999, Secretion of the galectin family of mammalian carbohydrate-binding proteins, Biochim Biophys Acta, 1473, 172, 10.1016/S0304-4165(99)00177-4

Nachtigal, 1998, Galectin-3 expression in human atherosclerotic lesions, Am J Pathol, 152, 1199

Iurisci, 2000, Concentrations of galectin-3 in the sera of normal controls and cancer patients, Clin Cancer Res, 6, 1389

Ishii, 2003, Prognostic value of combination of cardiac troponin T and B-type natriuretic peptide after initiation of treatment in patients with chronic heart failure, Clin Chem, 49, 2020, 10.1373/clinchem.2003.021311

Ishii, 2002, Risk stratification using a combination of cardiac troponin T and brain natriuretic peptide in patients hospitalized for worsening chronic heart failure, Am J Cardiol, 89, 691, 10.1016/S0002-9149(01)02341-4

Taniguchi, 2004, Combined measurements of cardiac troponin T and N-terminal pro-brain natriuretic peptide in patients with heart failure, Circ J, 68, 1160, 10.1253/circj.68.1160

Perna, 2004, Ongoing myocardial injury in stable severe heart failure: value of cardiac troponin T monitoring for high-risk patient identification, Circulation, 110, 2376, 10.1161/01.CIR.0000145158.33801.F3

Valgimigli, 2005, Tumor necrosis factor-alpha receptor 1 is a major predictor of mortality and new-onset heart failure in patients with acute myocardial infarction: the Cytokine-Activation and Long-Term Prognosis in Myocardial Infarction (C-ALPHA) study, Circulation, 111, 863, 10.1161/01.CIR.0000155614.35441.69

Aukrust, 1998, Elevated circulating levels of C-C chemokines in patients with congestive heart failure, Circulation, 97, 1136, 10.1161/01.CIR.97.12.1136

Weinberg, 2003, Identification of serum soluble ST2 receptor as a novel heart failure biomarker, Circulation, 107, 721, 10.1161/01.CIR.0000047274.66749.FE

Szokodi, 2002, Apelin, the novel endogenous ligand of the orphan receptor APJ, regulates cardiac contractility, Circ Res, 91, 434, 10.1161/01.RES.0000033522.37861.69

Tatemoto, 1998, Isolation and characterization of a novel endogenous peptide ligand for the human APJ receptor, Biochem Biophys Res Commun, 251, 471, 10.1006/bbrc.1998.9489

Hosoya, 2000, Molecular and functional characteristics of APJ, J Biol Chem, 275, 21061, 10.1074/jbc.M908417199

Ishida, 2004, Regulatory roles for APJ, a seven-transmembrane receptor related to angiotensin-type 1 receptor in blood pressure in vivo, J Biol Chem, 279, 26274, 10.1074/jbc.M404149200

Foldes, 2003, Circulating and cardiac levels of apelin, the novel ligand of the orphan receptor APJ, in patients with heart failure, Biochem Biophys Res Commun, 308, 480, 10.1016/S0006-291X(03)01424-4

McMurray, 2003, The rise and fall of myotrophin in heart failure, J Am Coll Cardiol, 42, 726, 10.1016/S0735-1097(03)00761-7

Bennett, 2002, Validity and reliability of the NYHA classes for measuring research outcomes in patients with cardiac disease, Heart Lung, 31, 262, 10.1067/mhl.2002.124554

Dolgin, 2005, Obesity and B-type natriuretic peptide levels in heart failure, J Am Coll Cardiol, 45, 967, 10.1016/j.jacc.2004.12.029